Video
SABCS 2021: Novel Approaches to Breast Cancer Management
After discussing a few more key datasets from the SABCS 2021 Virtual Meeting, expert panelists discuss how they would approach treatment in several subsets of breast cancer.
Data from the following clinical trials are discussed:
- GS3-03: Genomic analysis of 733 HER2+ breast cancer identifies recurrent pathway alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities
- GS1-05: Datopotamab deruxtecan (Dato-DXd) in advanced/metastatic HER2- breast cancer: results from the phase 1 TROPION-PanTumor01 study
- GS04-09: Quality-of-life results from OlympiA: a phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after neoadjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2- early breast cancer
Latest CME
View All
Video
Addressing Unmet Needs in HER2+ Metastatic BTC
Apr 18th 2025 - Apr 19th 2026
online-activity
Video
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Apr 17th 2025 - May 23rd 2025
online-activity
Video
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Apr 17th 2025 - May 23rd 2025
online-activity
Related Content
.png?fit=crop&auto=format)
.jpg?fit=crop&auto=format)
